- Home
- KNSA vs MLYS Comparison
KNSA vs MLYS Comparison
Compare KNSA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | MLYS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KNSA | MLYS |
|---|---|---|
| Price | $41.52 | $35.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $51.33 | $46.40 |
| AVG Volume (30 Days) | 345.4K | ★ 1.7M |
| Earning Date | 10-28-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | N/A |
| Revenue This Year | $62.63 | N/A |
| Revenue Next Year | $29.93 | N/A |
| P/E Ratio | $89.09 | ★ N/A |
| Revenue Growth | ★ 55.68 | N/A |
| 52 Week Low | $17.82 | $8.24 |
| 52 Week High | $42.98 | $47.65 |
Technical Indicators
Market Signals| Indicator | KNSA | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 36.67 |
| Support Level | $40.33 | $35.77 |
| Resistance Level | $42.32 | $39.15 |
| Average True Range (ATR) | 1.45 | 1.95 |
| MACD | -0.13 | -0.61 |
| Stochastic Oscillator | 56.68 | 0.70 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.